Drug Trial Radar · NCT00868959
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Last checked: Nov 20, 2026Latest source record: Apr 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
817
Actual
Start
Apr 2009
Primary completion
Feb 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
Conditions
- Bipolar Depression
Interventions
lurasidoneDrug
Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study TreatmentTime frame: 24 weeks
Locations
151 sites in 15 countries. Site status is shown where the registry gives one.
Woodland International Research Inc
Little Rock, Arkansas
South Coast Clinical Trials Inc.
Anaheim, California
Catalina Research Institute
Chino, California
Clinical Innovations Inc.
Costa Mesa, California
Synergy Escondido
Escondido, California
Collaborative Neuroscience Network Inc
Garden Grove, California
Cedars-Sinai Medical Center
Los Angeles, California
Florida Clinical Research Center LLC
Maitland, California
Excell Research, Inc
Oceanside, California
University of California at Irvine Medical Center
Orange, California
CNRI - Los Angeles LLC
Pico Rivera, California
Clinical Innovations Inc.
Riverside, California
California Neuropsychopharmacology Clinical Research Instit
San Diego, California
Artemis Institute for Clinical Research LLC
San Diego, California
Sharp Mesa Vista Hospital
San Diego, California
Clinical Innovations Inc.
Santa Ana, California
Stanford University School of Medicine
Stanford, California
Collaborative Neuroscience Network Inc.
Torrance, California
University of Colorado
Aurora, Colorado
MCB Clinical Research Centers-Colorado Springs
Colorado Springs, Colorado
Florida Clinical Research Center LLC
Bradenton, Florida
Florida Clinical Research Center LLC
Fruitland Park, Florida
Accurate Clinical Trials
Kissimmee, Florida
Clinical Neuroscience Solutions INc.
Orlando, Florida
University of South Florida Institute - Tampa
Tampa, Florida
Janus Center for Psychiatric Research
West Palm Beach, Florida
Northwest Behavioral Research Center
Rosewekk, Georgia
Institute for Behavioral Medicine LLC
Smyrna, Georgia
American Medical Research
Oak Brook, Illinois
Lake Charles Clinical Trials LLC
Lake Charles, Louisiana
Booker, J. Gary, MD. APMC
Shreveport, Louisiana
Sheppard Pratt Health System
Baltimore, Maryland
Capitol Clinical Research
Rockville, Maryland
Precise Research Centers
Flowood, Mississippi
Midwest Research Group
Saint Charles, Missouri
CRI Worldwide, LLC
Willingboro, New Jersey
Albuquerque Neuroscience Inc.
Albuquerque, New Mexico
Social Psychiatry Research Institute
Brooklyn, New York
Neurobehavioral Research, Inc
Cedarhurst, New York
Village Clinical Research Inc.
New York, New York
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.